The promises of precision medicine – voices from the Nordics

Edsjö A, Holmquist L, Geoerger B, Nowak F, Gomon G, Alix-Panabières C et al. Precision cancer medicine: concepts, current practice, and future developments. J Intern Med. 2023;294(4):455–81.

https://doi.org/10.1111/joim.13709 DOI: https://doi.org/10.1111/joim.13709

Horgan D, Tanner M, Aggarwal C, Thomas D, Grover S, Basel-Salmon L et al. Precision oncology: a global perspective on implementation and policy development. JCO Glob Oncol. 2025;11:e2400416.

https://doi.org/10.1200/GO-24-00416 DOI: https://doi.org/10.1200/GO-24-00416

van de Haar J, Roepman P, Andre F, Balmaña J, Castro E, Chakravarty D et al. ESMO Recommendations on clinical reporting of genomic test results for solid cancers. Ann Oncol. 2024;35:954–67.

https://doi.org/10.1016/j.annonc.2024.06.018 DOI: https://doi.org/10.1016/j.annonc.2024.06.018

Westphalen CB, Boscolo Bielo L, Aftimos P, Beltran H, Benary M, Chakravarty D et al. ESMO Precision Oncology Working Group recommendations on the structure and quality indicators for molecular tumour boards in clinical practice. Ann Oncol. 2025;36:614–25.

https://doi.org/10.1016/j.annonc.2025.02.009 DOI: https://doi.org/10.1016/j.annonc.2025.02.009

Taskén K, Haj Mohammad SF, Fagereng GL, Sørum Falk R, Helland Å, van Waalwijk van Doorn-Khosrovani SB et al. PCM4EU and PRIME-ROSE: collaboration for implementation of precision cancer medicine in Europe. Acta Oncol. 2024;63:34791.

https://doi.org/10.2340/1651-226X.2024.34791 DOI: https://doi.org/10.2340/1651-226X.2024.34791

Haj Mohammad SF, Timmer HJL, Zeverijn LJ, Geurts BS, Spiekman IAC, Verkerk K et al. The evolution of precision oncology: the ongoing impact of the Drug Rediscovery Protocol (DRUP). Acta Oncol. 2024;63:368–72.

https://doi.org/10.2340/1651-226X.2024.34885 DOI: https://doi.org/10.2340/1651-226X.2024.34885

Puco K, Fagereng GL, Brabrand S, Niehusmann P, Støre Blix E, Samdal Steinskog ES et al. IMPRESS-Norway: improving public cancer care by implementing precision medicine in Norway; inclusion rates and preliminary results. Acta Oncol. 2024;63:379–84.

https://doi.org/10.2340/1651-226X.2024.28322 DOI: https://doi.org/10.2340/1651-226X.2024.28322

Jalkanen KJ, Alanne E, Iivanainen S, Kääriäinen O-S, Tanner M, Auranen A et al. A national precision cancer medicine implementation initiative for Finland. Acta Oncol. 2024;63:395–7.

https://doi.org/10.2340/1651-226X.2024.32661 DOI: https://doi.org/10.2340/1651-226X.2024.32661

Belcaid L, Højgaard M, Tuxen I, Spanggaard I, Lassen U, Robinson L et al. Copenhagen Prospective Personalized Oncology (CoPPO) – impact of comprehensive genomic profiling in more than 2000 patients in a Phase I setting. Ann Oncol. 2025:S0923-7534(25)00158-9.

https://doi.org/10.1016/j.annonc.2025.04.004 DOI: https://doi.org/10.1016/j.annonc.2025.04.004

Kringelbach T, Højgaard M, Rohrberg K, Spanggaard I, Laursen BE, Ladekarl M, Haslund CA. ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling – a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial. Kringelbach et al. BMC Cancer. 2023;23:182.

https://doi.org/10.1186/s12885-023-10632-9 DOI: https://doi.org/10.1186/s12885-023-10632-9

Ny L, Fagman H, Botling J, Mantovaara L, Asplund P, Karlsson H et al. Feasibility and outcome of genomics-guided treatment selection in advanced cancer – the MEGALiT explorative clinical trial. Acta Oncol 2025;64:742-750.

https://doi.org/10.2340/1651-226X.2025.43366 DOI: https://doi.org/10.2340/1651-226X.2025.43366